Hydrochlorothiazide/ Olmesartan Medoxomil Aurobindo

Hydrochlorothiazide/Olmesartan Medoxomil Aurobindo is an oral tablet that combines the thiazide diuretic hydrochlorothiazide with the angiotensin II receptor blocker olmesartan medoxomil. This fixed‑dose combination is marketed in the European Union and is prescribed by healthcare professionals for the management of high blood pressure. By targeting two complementary pathways, the product aims to improve blood pressure control while simplifying the medication regimen for patients in clinical practice.

Hydrochlorothiazide/Olmesartan Medoxomil Aurobindo is indicated for the treatment of hypertension, particularly when monotherapy does not achieve target blood pressure.

- As initial therapy for patients requiring combined antihypertensive effect. - In patients already on separate olmesartan and hydrochlorothiazide who need a simplified regimen. - For individuals with salt‑sensitive hypertension where diuretic action adds benefit. - In cases where blood pressure control has been suboptimal with either component alone. - As part of a comprehensive cardiovascular risk‑reduction plan including lifestyle modification.

Like all antihypertensive agents, the combination may cause adverse reactions; the frequency and severity can vary among individuals.

Common: - Dizziness or light‑headedness, especially after the first dose. - Increased urination or mild electrolyte changes such as low potassium. - Headache. - Fatigue or weakness.

Serious: - Severe dehydration or electrolyte imbalance (e.g., hyponatremia, hypokalemia). - Acute kidney injury or significant rise in serum creatinine. - Allergic reactions including rash, angioedema, or anaphylaxis.

Healthcare providers should evaluate patient history and laboratory values before prescribing Hydrochlorothiazide/Olmesartan Medoxomil Aurobindo.

- Assess renal function; avoid use in severe renal impairment. - Monitor electrolytes, particularly potassium and sodium, during therapy. - Use caution in patients with a history of gout, as thiazides may increase uric acid. - Evaluate for hepatic disease, as olmesartan is metabolized in the liver. - Consider pregnancy status; the safety profile in pregnancy is not established. - Review concomitant use of other antihypertensives to prevent excessive blood‑pressure reduction. - Advise patients to rise slowly from sitting or lying positions to reduce orthostatic dizziness.

The fixed‑dose combination can interact with several medicines; awareness of these interactions helps prevent adverse outcomes.

Avoid: - Concurrent use with other potent diuretics or potassium‑sparing agents, which may cause severe electrolyte disturbances. - Co‑administration with aliskiren in patients with diabetes or renal impairment. - Use with strong CYP3A4 inhibitors (e.g., ketoconazole) that may increase olmesartan levels.

Use with caution: - NSAIDs, which can blunt antihypertensive effect and affect renal function. - Lithium, as thiazides may raise lithium concentrations. - ACE inhibitors or other ARBs, increasing risk of hyperkalemia and renal impairment. - Beta‑blockers, which may enhance blood‑pressure lowering.